The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression

Autor: Zhenghong Li, Carrie Sun, Sijia Tao, Adeboye O. Osunkoya, Rebecca S. Arnold, John A. Petros, Xiongbing Zu, Carlos S. Moreno

Publikováno v: Translational Oncology, Vol 13, Iss 4, Pp - (2020)

In our previous study, we observed that androgen deprivation therapy (ADT) may induce a compensatory increase in MAPK or JNK signaling. Here, we tested the effects of the MEK inhibitors PD0325901 and GSK1120212, ERK1/2 inhibitor GDC-0994, and the JNK

Externí odkaz: https://doaj.org/article/b5534da476654170a8fe631f6ae4cb67

Correction: Antibody Responses against Xenotropic Murine Leukemia Virus-Related Virus Envelope in a Murine Model.

Autor: Natalia Makarova, Chunxia Zhao, Yuanyuan Zhang, Sushma Bhosle, Suganthi Suppiah, Jeanne M. Rhea, Natalia Kozyr, Rebecca S. Arnold, Hinh Ly, Ross J. Molinaro, Tristram G. Parslow, Eric Hunter, Dennis Liotta, John Petros, Jerry L. Blackwell

Publikováno v: PLoS ONE, Vol 6, Iss 5 (2011)

Externí odkaz: https://doaj.org/article/14aec9171bfa40f4b070f3cf317d9a4c

Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics

Autor: Arthur S. Edison, David L. Roberts, Sharon H Bergquist, Samyukta Sah, Kenneth Ogan, David A. Gaul, Olatomiwa O Bifarin, Facundo M. Fernández, John A. Petros, Rebecca S. Arnold, Viraj A. Master

Publikováno v: J Proteome Res

Renal cell carcinoma (RCC) is diagnosed through expensive cross-sectional imaging, frequently followed by renal mass biopsy, which is not only invasive but also prone to sampling errors. Hence, there is a critical need for a noninvasive diagnostic as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541f7119a9d7c9df03f6af53f2cf5d07
https://doi.org/10.1021/acs.jproteome.1c00213

Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Autor: Marc A. Dall'Era, R. Jeffrey Karnes, Jacqueline Petkewicz, Michael S. Cookson, Eric A. Klein, Soroush Rais-Bahrami, Jeremiah R. Dallmer, Kelly L. Stratton, Phillip R. Cooper, Denise M. Scholtens, James A. Eastham, Janet L. Stanford, Rebecca S. Arnold, Peter R. Carroll, S. Larry Goldenberg, Monique J. Roobol, Niall M. Corcoran, Lisa F. Newcomb, Stephen Farriester, Antonio Finelli, Nicola Lancki, Nataliya Byrne, Thomas Flynn, Neil E. Fleshner, Anthony J. Costello, Christian P. Pavlovich, Rabia Martin, Matthew R. Cooperberg, John S. Witte, Ann Martinez, Leonard S. Marks, Lauren Folgosa Cooley, Mufaddal Mamawala, Martin G. Sanda, Lionne D.F. Venderbos, Joel B. Nelson, Maria Spillane, Nicholas Kirwen, Sergio Garza, Erin Hemken, William J. Catalona, Shilajit Kundu, Paige Gotwald, Courtney Phares, Fernando J. Bianco, Tuula Pera, Justin R. Gregg, Todd M. Morgan, June M. Chan, Dawn McBride, Courtney Rose Dhondt, Andrew Loblaw, Jeri Kim, Maria Komisarenko, Brian T. Helfand, Deimante Banionyte, Karen Brittain, Janet E. Cowan, Christopher P. Evans, Walter M. Stadler, Danny Vesprini, Linda Kachuri, Franklin Gaylis, Danielle Barsa, Yu Jiang, Javed Siddiqui, Cherie Perez, Isabel H. Lopez, Daniel W. Lin, Travis J. Meyers, Alexandre Mamedov, Tricia Landis, Ken Chow, Luc Boileau, Douglas S. Scherr, Christopher J. Logothetis, Celestia S. Higano, Merdie Delfin, Stacy Loeb, Adaeze A. Emeka, Anjali Vij, Jennifer B. Gordetsky, Irene Helenowski, Laurence Klotz, Pam Steele, Suzanne Kolb, Eugenia Wu, Christopher L. Amling, DA Barocas, Samir S. Taneja, Michael O. Koch, Dattatraya Patil, Behfar Ehdaie, Jazmine Stockdale, Nicole Benfante, H. Ballentine Carter, Jianfeng Xu

Publikováno v: Human Genetics and Genomics Advances
HGG Advances, Vol 3, Iss 1, Pp 100070-(2022)
Human Genetics and Genomics Advances, 3(1):100070. Cell Press
HGG advances, vol 3, iss 1

Summary Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef05bc911ab1518924ae422daa169dd1
http://europepmc.org/articles/PMC8725988

Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents

Autor: Samuel G. Moore, David A. Gaul, Subhasish Tapadar, Bocheng Wu, Rebecca S. Arnold, John A. Petros, Adegboyega K Oyelere, Shaghayegh Fathi, Idris O. Raji, Carrie Q. Sun

Publikováno v: Cancers
Volume 12
Issue 11
Cancers, Vol 12, Iss 3095, p 3095 (2020)

Simple Summary Liver cancers are among the leading causes of global cancer deaths. The current therapy options for liver cancers, including hepatocellular carcinoma (HCC), which accounts for over 80% of all cases, have afforded limited benefit to pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7469ae3ccfb04dabfbae4bb44a87e13